“Creating positive achievements with our
customers by helping them adapt successfully
to a changing environment is in essence
- Larry MacGirr, COO
"Partnership is valuable to us.
Our goal is not only to meet but
exceed our customers’ expectations."
New contraindication for concomitant use of these drugs.
Pharmascience Inc. to Invest More Than $55 Million to Upgrade its R&D and Manufacturing Facilities in Greater Montreal.
Pendopharm enters into an exclusive distribution agreement for the commercialisation rights to non-prescription NASACORT®ALLERGY 24HR (triamcinolone acetonide) in Canada.